Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

NCT01465347
completedphase_1

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

NCT00725881
terminatedphase_1

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

NCT00826930

Clinical Trials (3)

Showing 3 of 3 trials
NCT01465347Phase 1

Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

Completed
NCT00725881Phase 1

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

Completed
NCT00826930Phase 1

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3